辅助吉非替尼治疗独特的时空治疗失败模式:ADJUVANT试验(CTONG 1104)的事后分析
本文为ADJUVANT研究(CTONG 1104)的事后分析,纳入222例N1-N2期EGFR突变非小细胞肺癌术后患者,比较吉非替尼与长春瑞滨联合顺铂(VP)治疗失败模式。吉非替尼组首次转移部位以中枢神经系统最常见(27.4%),VP组以颅外转移最常见(36.8%);吉非替尼组术后0至21个月复发率低于VP组。
要点
- 吉非替尼组首次转移以中枢神经系统最常见,为106例中29例(27.4%)。
- VP组首次转移以颅外转移最常见,为87例中32例(36.8%)。
- 吉非替尼组术后12个月起复发呈持续上升趋势。
核心结论
- 辅助吉非替尼在治疗失败模式上优于VP化疗,尤其在颅外转移方面。
- 作者认为,辅助酪氨酸激酶抑制剂可考虑作为N1-N2期EGFR突变NSCLC术后治疗选择,但需探索更长疗程。
研究设计与样本
- ADJUVANT研究(CTONG 1104)的事后分析。
- 共222例N1-N2期EGFR突变NSCLC患者接受吉非替尼或长春瑞滨联合顺铂(VP)治疗。
- 对改良意向治疗人群以Kaplan-Meier法和风险率曲线估计治疗失败模式。
主要发现
- 共124个进展事件,包括114例复发和10例复发前死亡。
- 空间分布分析显示,吉非替尼组首次转移部位以中枢神经系统最常见,为106例中29例(27.4%)。
- VP组颅外转移最常见,为87例中32例(36.8%)。
- 时间分布分析显示,术后0至21个月吉非替尼组肿瘤复发低于VP组;但吉非替尼组术后12个月起复发呈持续上升。
- 颅外转移首个高峰:VP组为术后9至15个月,吉非替尼组为24至30个月;中枢神经系统转移最高峰:VP组为术后12至18个月,吉非替尼组为24至36个月。
临床怎么用
- 作者认为,辅助酪氨酸激酶抑制剂可考虑作为N1-N2期EGFR突变NSCLC术后治疗选择,但需探索更长疗程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adjuvant gefitinib therapy prolonged disease-free survival in patients with resected early-stage EGFR-mutation positive NSCLC in the ADJUVANT study (CTONG 1104). However, treatment failure patterns after gefitinib therapy are less well characterized. METHODS: Overall, 222 stage N1-N2, EGFR-mutant NSCLC patients received gefitinib or vinorelbine plus cisplatin (VP) treatment. Tumor recurrences or metastases occurring during follow-up were defined as treatment failure; sites and data of first treatment failure were recorded. A post hoc analysis of treatment failure patterns which was estimated by Kaplan-Meier and hazard rate curves in modified intention-to-treat patients was conducted. RESULTS: There were 114 recurrences and 10 deaths before recurrence across 124 progression events. Spatial distribution analysis showed that the first metastasis site was most frequently the central nervous system in the gefitinib group (29 of 106 [27.4%]), extracranial metastases were most frequent in the VP group (32 of 87 [36.8%]). Temporal distribution analysis showed lower tumor recurrence with gefitinib than with VP 0 to 21 months post-surgery. However, recurrence with gefitinib showed a constant rate of increase 12 months post-surgery. The first peak of extracranial metastasis appeared during 9 to 15 months with VP and 24 to 30 months with gefitinib. The highest peak for central nervous system metastases post-surgery occurred after 12 to 18 months with VP and 24 to 36 months with gefitinib. CONCLUSIONS: Adjuvant gefitinib showed advantages over VP chemotherapy in treatment failure patterns especially in extracranial metastasis. Adjuvant tyrosine kinas inhibitors may be considered as a treatment option in resected stage N1-N2 EGFR-mutant NSCLC but longer duration should be explored.
引用
- Xu ST, Xi JJ, Zhong WZ, et al. The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104). J Thorac Oncol. 2018. PMID: 30521970. doi:10.1016/j.jtho.2018.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。